Laboratory Analytical Instruments · DE · CIK 1314102
EyePoint develops and commercializes therapeutics for serious retinal diseases, aiming to improve patient lives and reduce follow-up care frequency
Comparable business profile · signals at a glance
In the 90 days to Mar 16, 2026: 1 insider bought $20K · 1 sold $808K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Duker Jay S.President and CEO | Buy | 1,500 | $13.15 | $20K |
| Mar 4, 2026 | Ribeiro RamiroChief Medical Officer | Sell | 2,438 | $17.87 | $44K |
| Feb 17, 2026 | Ribeiro RamiroChief Medical Officer | Sell | 2,437 | $15.00 | $37K |
| Jan 5, 2026 | Ribeiro RamiroChief Medical Officer | Sell | 42,544 | $17.10 | $728K |
| Dec 4, 2025 | Cormorant Asset Management, LpOther | Sell | 60,000 | $15.70 | $942K |
| Dec 4, 2025 | Lurker NancyDirector | Sell | 9,300 | $15.11 | $141K |
| Nov 28, 2025 | Lurker NancyDirector | Sell | 500 | $14.95 | $7K |
| Nov 26, 2025 | Lurker NancyDirector | Sell | 200 | $14.95 | $3K |
| Nov 11, 2025 | Ribeiro RamiroChief Medical Officer | Sell | 2,722 | $11.61 | $32K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.